CLinDMA

Cat. No.: HY-112763

CAS No.: 908860-82-2

Molecular Formula: $C_{54}H_{97}NO_3$

Molecular Weight: 808.35

Target: Liposome

Pathway: Metabolic Enzyme/Protease

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 140 mg/mL (173.19 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.2371 mL	6.1854 mL	12.3709 mL
	5 mM	0.2474 mL	1.2371 mL	2.4742 mL
	10 mM	0.1237 mL	0.6185 mL	1.2371 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 3.5 mg/mL (4.33 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 3.5 mg/mL (4.33 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CLinDMA, a cationic lipid, can cause inflammatory response. CLinDMA can be used for the synthesis LNP201. LNP201 is a liposome assembly for systemic delivery of siRNA[1].

In Vitro

LNP201 causes sustained silencing of the murine Ssb gene in the mouse liver after single or multiple doses through an RNAi mechanism. LNP201 causes an acute inflammatory response, inducing expression of numerous genes involved in innate immunity as well as mitogen-activated protein kinase (MAPK) phosphorylation in tissues[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Abrams MT, et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther. 2010;18(1):171-180.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA